Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Duavee (conjugated estrogens/bazedoxifene) is indicated in women with a uterus for the treatment of moderate to severe vasomotor symptoms associated with menopause and for the prevention of postmenopausal osteoporosis.
• This summary is based on the review of three systematic review(s)/meta-analysis(es). ^[1-3]
• Fezolinetant 45 mg significantly reduced the frequency of moderate to severe vasomotor symptoms (VMS) compared to non-hormonal therapies (paroxetine, desvenlafaxine, gabapentin ER) and placebo but did not show significant differences compared to hormone therapy (HT) regimens. It was less effective than tibolone 2.5 mg in reducing VMS severity.
• Bazedoxifene (BZA) 20 mg plus conjugated estrogens (CE) 0.625 mg significantly reduced the daily number of hot flushes, improved sleep disturbances, and enhanced total Menopause-Specific Quality of Life (MENQOL) compared to placebo, with greater effectiveness noted for the higher dosage compared to BZA 20 mg/CE 0.45 mg.
• BZA/CE demonstrated significant benefits for sleep disturbances associated with vasomotor symptoms compared to placebo/control, with similar effectiveness to gabapentin and oral combined hormone therapy.
• Dropout rates due to adverse events were comparable between BZA/CE and placebo/control, while eszopiclone and oral combined hormone therapy showed higher rates of discontinuation due to adverse events.
• There is no population types or subgroups information available in the reviewed studies.